ABIONYX Pharma Announces Its Financial Agenda for the Year 2020

TOULOUSE, France & LAKELAND, Mich.--()--Regulatory News:

ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2020.

Events

Date*

Cash position and activity update for Q4 2019

February 4, 2020

2019 Annual Results

March 19, 2020

Cash position and activity update for Q1 2020

April 23, 2020

Cash position and activity update for Q2 2020

July 23, 2020

2020 Half Year Results

September 10, 2020

Cash position and activity update for Q3 2020

October 22, 2020

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.

Contacts

NewCap
Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
abionyx@newcap.eu
+33 (0)1 44 71 94 98

Contacts

NewCap
Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
abionyx@newcap.eu
+33 (0)1 44 71 94 98